A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To preliminarily evaluate the efficacy of the treatment regimen of HBM9161
680 mg administered subcutaneously weekly and sequentially every other week for 12 weeks in
Chinese patients with active moderate to severe TED.